Search

Search results

59 results found

Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.

Nardella, Caterina, Andrea Lunardi, Giuseppe Fedele, John G Clohessy, Andrea Alimonti, Sara C Kozma, George Thomas, Massimo Loda, and Pier Paolo Pandolfi. 2011. “Differential Expression of S6K2 Dictates Tissue-Specific Requirement for S6K1 in Mediating Aberrant MTORC1 Signaling and Tumorigenesis.”. Cancer Research 71 (10): 3669-75.

In Vivo Protocol Design and Implementation

Agents alone or in combination will be evaluated in vivo in human tumor xenografts in mice, as well as in GEMs obtained by outsourcing or in-house acquisition when requested. We will evaluate each drug or combination of drugs by different routes or different schedules of administration following...

NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.

Morel, Katherine L, Anis A Hamid, John G Clohessy, Nicole Pandell, Leigh Ellis, and Christopher J Sweeney. 2021. “NF-κB Blockade With Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.”. Molecular Cancer Research : MCR 19 (7): 1137-45.